? NUTRIENT AND PHYTOCHEMICAL ANALYTICS SHARED RESOURCE (NPASR) The mission of the NPASR is to provide niche services supporting research with high quality assays for biomarkers of tobacco exposure, specific nutrients, or a vast array of anti-cancer phytochemicals found in food sources. NPASR primarily supports the Molecular Carcinogenesis and Chemoprevention (MCC) and the Cancer Control (CC) Programs, which have robust research examining the role of diet and tobacco in cancer etiology, prevention, and survivorship. The NPASR co-Directors are Drs. Steven Clinton, a translational researcher in cancer prevention (interim co-Director, Senior Faculty Advisor; MCC co-Leader) and Devin Peterson, a senior food science chemist in the College of Food, Agricultural, and Environmental Sciences.
The Specific Aims of the NPASR are to: 1) provide expert, leading-edge bioanalytical method development and quantitative analysis of nutrients and bioactive phytochemicals in foodstuffs; 2) conduct targeted quantitative analysis of nutrients, bioactive phytochemicals and their metabolites in biological samples generated from in vitro, in vivo and human studies using HPLC-MS/MS techniques; and 3) perform untargeted metabolomics and lipidomics services for cancer-related studies. NPASR technologies include state-of-the-art ultra-high performance liquid chromatography (UHPLC), mass spectrometry (MS) and liquid chromatography triple quadrupole MS/MS (LC- MS/MS). NPASR has added several new analytical capabilities during the current funding cycle including: 1) ion mobility hardware facilitating a broad semi-quantitative lipidomics platform; 2) a second MS instrument to support untargeted metabolomics and lipidomics demand; and 3) a state-of-the-art MS/MS for utmost sensitivity. During the current funding cycle, the NPASR supported 49 publications (2 > 10 impact factor), 55 users, and 6 NCI grants, including 1 P50, 3 R01s, 1 U19 and 1 U01, involving all five CCC programs. These efforts and publications have contributed to defining biomarkers of exposure or intake, and provided novel insight into phytochemical absorption, distribution, metabolism, and excretion. More recently, NPASR has expanded into targeted and untargeted metabolomics supporting our understanding of individual cancer risk due to tobacco exposure, nutrients, specific foods, and dietary patterns. To meet future demands of OSUCC Investigators aligned with OSUCCC strategic priorities, NPASR will further support, for example, studies of metabolomic- microbiome interactions, genetic determinants of metabolism and tobacco use biomarkers. During the next grant cycle, lipidomics and bioactive lipid analytic capabilities will be expanded to meet the needs of a growing user base of all five programs. The NPASR provides a critical service for CCC members evaluating foods, nutrients and carcinogens that spans research disciplines from cell culture and experimental animal studies to human trials and molecular epidemiology. The annual budget of the NPASR is $387,249, yet the CCSG request is $74,239. As such, the NPASR leverages extensive institutional support and seeks only 19.2% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090015
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Qian, Maoxiang; Cao, Xueyuan; Devidas, Meenakshi et al. (2018) TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 36:591-599
Myers, Regina M; Hill, Brian T; Shaw, Bronwen E et al. (2018) Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer 124:816-825
Nemeth, Julianna M; Thomson, Tiffany L; Lu, Bo et al. (2018) A social-contextual investigation of smoking among rural women: multi-level factors associated with smoking status and considerations for cessation. Rural Remote Health 18:4338
Mace, Thomas A; Shakya, Reena; Pitarresi, Jason R et al. (2018) IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67:320-332
Massengill, James B; Sample, Klarke M; Pilarski, Robert et al. (2018) Analysis of the exome aggregation consortium (ExAC) database suggests that the BAP1-tumor predisposition syndrome is underreported in cancer patients. Genes Chromosomes Cancer 57:478-481
Buteyn, Nathaniel J; Fatehchand, Kavin; Santhanam, Ramasamy et al. (2018) Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int Immunol 30:375-383
Orchard, Tonya S; Andridge, Rebecca R; Yee, Lisa D et al. (2018) Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. J Acad Nutr Diet 118:578-588.e1
Reiff, Sean D; Mantel, Rose; Smith, Lisa L et al. (2018) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov 8:1300-1315
Pi, Fengmei; Binzel, Daniel W; Lee, Tae Jin et al. (2018) Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 13:82-89

Showing the most recent 10 out of 2602 publications